About Adjuvant Capital
Adjuvant Capital is a company based in New York City, USA. It operates as a Commission-Based. Adjuvant Capital offers products and services including Venture Financing for Global Health.
- Headquarter New York City, USA
- SectorsFinancial Services
- Email••••••••
- Website adjuvantcapital.com
Products & Services of Adjuvant Capital
Adjuvant Capital offers a comprehensive portfolio of products and services, including Venture Financing for Global Health.
Venture capital is provided for global health innovations.
People of Adjuvant Capital
10 people are tracked at Adjuvant Capital (7 in leadership, 2 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Curt Labelle | Venture Partner | Leadership |
Charlie Petty | Venture Partner | Leadership |
Gerard Cunningham | Operating Partner | Leadership |
Mark Sullivan | Venture Partner | Leadership |
Evelyn Yanatos | Director of Finance & Compliance | Leadership |
Glenn Rockman | Founder And Managing Partner | Leadership |
Philippe Dro | Partner | Leadership |
Jim Robinson | Senior Advisor | Board & advisors |
Christian Mandl | Senior Advisor | Board & advisors |
Giulia Balconi | Life Sciences Venture Capital | Team |
Complete people profiles for Adjuvant Capital
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Similar companies to Adjuvant Capital
10 companies that operate in the same segment as Adjuvant Capital (Venture Capital Funds), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Network connecting investors to startups, venture capital funds, and alternatives | 2013 | Jerusalem, Jerusalem District, Israel | USD 35 M | – | – | |
Venture capital firm investing in early-stage tech startups | 1972 | Menlo Park, California, United States | USD 1.2 B | – | – | |
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | Redwood City, California, United States | – | USD 691.23 K | – | |
Accel is recognized as a leading venture capital firm. | 1983 | Palo Alto, California, United States | – | – | – | |
Early-stage startup ecosystem is supported by Venture Catalysts in India. | 2015 | Mumbai, Maharashtra, India | – | USD 3.32 M | – | |
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | Menlo Park, California, United States | – | – | 42 | |
Venture capital fund and startup incubator for healthcare and agricultural companies | 1993 | Misgav, Northern District, Israel | – | USD 1.99 M | 23 | |
Management consulting services are provided to organizations worldwide. | 1965 | Brisbane, Queensland, Australia | – | – | – | |
Multiple sectors are invested in by this venture capital firm. | 1987 | Sao Paulo, Brazil | – | USD 715.62 M | – | |
Early-stage startups are funded by this venture capital firm. | 2004 | Menlo Park, California, United States | – | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adjuvant Capital
Venture capital strategies are utilized by Adjuvant Capital to invest in promising life science technologies addressing high-burden public health challenges. Focus areas include infectious diseases such as HIVAIDS, tuberculosis, and malaria, as well as maternal and child health, nutrition, and reproductive health. Investments are primarily made in technologies demonstrating safety and efficacy in humans, with an aim to accelerate global availability of impactful medical innovations. Emerging markets and underserved populations are targeted to achieve health equity and differentiated financial returns. Global trends like climate change, urbanization, and antimicrobial resistance are considered in shaping investment decisions.
Adjuvant Capital offers Venture Financing for Global Health.